Author name: Emily Crane

Emily Crane is a writer, producer, and editor who has covered politics, health, business, and finance for publications like The Atlantic. She's also the host of the All Work All Play Podcast. She graduated from Northwestern University's Medill School of Journalism with a focus on investigative reporting and data visualization.

Avatar of Emily Crane
108101530 1739386738587 gettyimages 1966457733 cfoto apharmac240131 np793

U.S. investors, Big Pharma race to find new medicines in China

Health & Fitness / By

A little-known biotech company stunned the biopharmaceutical industry last spring when it declared an “unprecedented” achievement: its experimental cancer drug looked more effective than Merck‘s Keytruda in a clinical trial. The company, Summit Therapeutics, licensed the drug from Chinese company Akeso Inc.  In October, a group of life science investors announced they were putting $400 […]

U.S. investors, Big Pharma race to find new medicines in China Read More »

All Work All Play Podcast

A year in beauty: CosmeticsDesign unpacks key developments in 2024 that will impact 2025

Fashion & Beauty / By

In this episode of the Beauty 4.0 Podcast, the CosmeticsDesign editorial team looked back on the highlights of 2024. Kirsty Doolan, editor of CosmeticsDesign-Europe, said there were some surprises that she did not expect in 2024, including L’Oréal’s minority acquisition of Galderma. “Earlier in the year, I would have considered them to be rival companies.

A year in beauty: CosmeticsDesign unpacks key developments in 2024 that will impact 2025 Read More »

108100580 1739281416248 gettyimages 2194484256 PWeaver 250120 22

CVS shares pop 15% on big earnings beat, even as high medical costs drag down insurance unit

Health & Fitness / By

CVS Health on Wednesday reported fourth-quarter revenue and profit that topped estimates, even as its troubled insurance business continued to see higher medical costs.  The company also issued a full-year 2025 adjusted earnings outlook of $5.75 to $6 per share, which was in line with Wall Street’s expectations. But CVS did not provide a revenue

CVS shares pop 15% on big earnings beat, even as high medical costs drag down insurance unit Read More »

108031149 1725902752106 gettyimages 2171009958 js2 5976 kuckmxna

Apple launches first major health study in 5 years. Here's how you can opt in

Health & Fitness / By

Apple is deepening its investment in health-care research by launching a new, yearslong project called the Apple Health Study, the company announced Wednesday.  The study will analyze how data from devices such as iPhones, AirPods and Apple Watches can monitor, manage and predict changes in users’ health. It will also explore connections between different components

Apple launches first major health study in 5 years. Here's how you can opt in Read More »

New construction technology releases: February 2025

Building & Construction / By

Listen to the article 8 min This audio is auto-generated. Please let us know if you have feedback. From updated exoskeletons to an AI agent that doesn’t complain about busywork, the latest construction technology releases have your back.  Here, Construction Dive breaks down six of the latest products and enhancements to hit the market in

New construction technology releases: February 2025 Read More »

107169298 1671576446191 gettyimages 1224202684 a244 c040 01015j 01

Healthy Returns: What to know about Trump's NIH funding cuts

Health & Fitness / By

A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The Trump administration is trying to implement major funding cuts to the National Institutes of Health that would cap medical and public health research payments to universities,

Healthy Returns: What to know about Trump's NIH funding cuts Read More »

108049619 1729251522779 gettyimages 1253662206 SENATE INSULIN

CVS CEO defends pharmacy middlemen, accuses drugmakers of 'monopolistic' practices

Health & Fitness / By

CVS Health CEO David Joyner on Wednesday defended controversial pharmacy middlemen like his company’s Caremark unit, which are widely accused of inflating prescription medication prices, and instead accused manufacturers of “monopolistic tendencies” that keep drug costs high in the U.S.  Joyner, who stepped into the role in October, spent much of his opening remarks on

CVS CEO defends pharmacy middlemen, accuses drugmakers of 'monopolistic' practices Read More »

Start typing and press enter to search

Scroll to Top